Cytokines playa central role in the pathogenesis of allergic diseases and allergic inflammation (I). Therefore, an understanding of the mechanisms which regulate production and function of cytokines is very important and may result in the development of more effective methods of treatment of allergic diseases. .Allergic inflammatory responses are driven by cells of the immune system that rely on cytokines to regulate the activity of other immune and structural cells (2) .
Pro-inflammatory cytokines, particularly those encoded as chromosome 5q including interleukin (IL)-4, IL-5, and GM-CSF along with, TNF-alpha play a role in allergen-induced.airway leukocyte recruitment and these cytokises canbe generated not only by T cells but also by mast cells and other cells (3) (4) (5) . The early cell recruitment within 6 hrs of challenge is likely to be mast cell determined (6) (7) , with a potential but undefined contribution from alveolar macrophages as this cell population can generate TNF-alpha and IL-1-beta, inflammatory cells that are of importance to endothelial leukocyte adherence (8) . The elaboration of cytokines from T cells contribute to the perpetuation of this response as do chemokine and cytokine generation by airway epithelial cells (9) . The potential for a down-regulation role to modulate these events by T lymphocytes and macrophages is also apparent, with IL-lO generation by these cells 24 hrs post-challenge (10) .
Moreover, complex interaction between cytokines and cells will also serve to regulate this process as GM-CSF, while promoting airway eosinophil retention, has been shown to inhibit tryptase production by epithelial mast cells and this protease can be linked with epithelial activation (11) (12) . Inflammatory cells, through the secretion of cytokines and pro-inflammatory molecules, are thought to playa critical role in pathogenesis (13) (14) . Type 2 CD4(+) lymphocytes (Th2 cells) and their cytokines predominate in mild to moderate allergic diseases (15) (16) . Other immune cells, particularly neutrophils, macrophages and dendritic cells, as well structural cells such as epithelial and airway smooth muscle cells also produce disease-associated cytokines in allergic diseases such as asthma (17) . Increased levels ofthese immune cells and cytokines have been identified in clinical samples and their potential role in disease was demonstrated in studies using mouse models of asthma (18) (19) .
IL-13, IL-9 and granulocyte-macrophage colonystimulating factor are currently being evaluated in clinical trials or preclinically and the outcome of these studies is eagerly awaited (20) . Roles for IL-25, IL-33, interferon-y, IL-17 and IL-27 in the regulation of asthma are just emerging, identifying new ways to treat inflammation (21) . Careful interpretation of results from mouse studies will inform on the development and application of therapeutic approaches for asthma (22) . The most effective approaches may be combination therapies that suppress multiple cytokines and a range of redundant and disconnected pathways that separately contribute to asthma pathogenesis (23) .
Cytokine mRNA and protein expression has been assessed in lavage and biopsy samples at 18-24 h post-allergen challenge, to investigate cytokine up-regulation and generation at this late time point (24) (25) (26) . In some experimental animals, samples 24 h post-allergen challenge, there is an increased proportion of activated CD4+ T cells and in situ hybridization has revealed increased numbers ofcells expressing mRNA for IL-4, IL-5, and GM-CSF, but not IL-2, IL-3 or IFN-gamma (27) . Consistent with this, the IL-4 and IL-5 mRNA are predominantly confined to T cells (28) . However, in endobronchial biopsies there is no increase in absolute T cell numbers in the 24 h following allergen challenge (29) . There is, however, an increase in the number of cells expressing IL-5 and GM-CSF (30) . The cellular origin for these cytokines has not been defined, but in addition to T lymphocytes these cytokines may be expressed both by mast cells and infiltrating eosinophils (31) . In addition to a pro-inflammatory action through an increase in TH2 cytokine synthesis, T cells may serve a down-regulatory role. IL-4 is known to regulate the function of a variety of cells ofthe immune system (32) . IL-4 has been previously shown to inhibit the synthesis of pro-inflammatory cytokines such as IL-1 beta and TNF alpha by LPSstimulated human peripheral blood mononuclear cells (33) . These pro-inflammatory cytokines are also produced in response to IL-2 and are thought to contribute to the toxicity associated with IL-2 immunotherapy (34) . IL-4 is a potent regulator of IL-2-induced pro-inflammatory cytokine expression (32) . Its suppressive effects are dependent on new protein synthesis and, in the case of IL-l beta, partly attributable to destabilization of cytokine mRNA (33) . These cytokines orchestrate the recruitment and activation of different effector cells, such as eosinophils and mast cells (35) . These cells, along with Th2 cytokines, are key players in the development of chronic allergic inflammatory disorders, usually characterized by airway hyperresponsiveness, reversible airway obstruction, and airway inflammation (36) . Accumulating evidence has shown that altering cytokine-producing profile of Th2 cells by inducing Th1 responses may be protective against Th2-related diseases such as asthma and allergy (37) . Interferon-gamma (IFNgamma), the principal Thl effector cytokine, has shown to be crucial for the resolution of allergicrelated immunopathologies (38) . In fact, reduced production of this cytokine has been correlated with severe asthma.
Interleukin-18 (IL-18) has been regarded as a proinflammatory cytokine because of its potent interferon-gamma-inducing activity (39) . However, mutant mice that release excess amounts of IL-18 spontaneously develop pruritic chronic dermatitis-like atopic dermatitis (AD), suggesting the importance of IL-18 for the development of AD (40) . Intriguingly, depletion of IL-18 but not stat6, an essential transcriptional factor for IL-4 signaling, rescues the mice from AD, indicating IL-l8-dependent, T-helper2 (Th2) cell-independentAD (41) .
Inflammatory mediators produced from activated mast cells and Th2 cells drive allergic inflammation (42) . The pathways required for mast and Th2 cell activation and the effects of their products are being defined in order to identify new therapeutics. Th2 cells induce allergic inflammation through the production of cytokines such as IL-4, IL-5 and IL-13 (43) . Recently, it has been demonstrated that a novel IL-17 family cytokine IL-25 (IL-17E) is a product of activated Th2 cells and mast cells (44) . IL-25 induces IL-4, IL-5 and IL-13 production from undefined non-T/non-B cells and then induces Th2-type immune responses such as blood eosinophilia and increased serum immunoglobulin E levels (45) . Therefore, IL-25 plays an important role in enhancing allergic airway inflammation by a CD4+ T-cell-dependent mechanism (46) . (47) . IL-4 also has a central role in the pathogenesis of allergic inflammation.IL-4 and IL-13, known mast cell products, also induce bronchial hyperresponsiveness in the mouse, independent of the inflammatory response, and enhance the magnitude of agonist-induced intracellular Ca 2 + responses in cultured human airway smooth muscle (48) . There are therefore many pathways by which the close approximation of mast cells with airway smooth muscle cells might lead to disordered airway smooth muscle function (49) .
IL-4 is crucial for the differentiation of naive T helper [T(h)] cells into the T(h)2 effector cells that promote humoral immunity and provide protection against intestinal helminthes
Bronchial asthma is a complex disease characterized by airway inflammation involving a Th2-cytokine, '1L-13 (50) . A substantial body of evidence has accumulated pointing to the pivotal role of IL-13 in the pathogenesis of bronchial asthma. The evidence is categorized as a) analyses of mouse models, b) expression of these cytokines in the bronchial lesions, and c) genetic association of the signaling molecules of these cytokines (51) . In addition, the molecular mechanism of the signal transduction of IL-13 has also been well characterized (52) .
Mast cells also infiltrate the airway mucous glands in subjects with asthma, showing features of degranulation, and a positive correlation with the degree of mucus obstructing the airway lumen, suggesting that mast cells play an important role in regulating mucous gland secretion (53) . The development of potent and specific inhibitors of mast cell secretion, which remain active when administered long-term to asthmatic airways, should offer a novel approach to the treatment of asthma (54) .
Accumulating evidence indicates that T helper type 2 cell-derived cytokines play critical roles in orchestrating and amplifying allergic inflammation (55) . In addition, it has been suggested that newly identified cytokines, including IL-25 and IL-33, are involved in the induction of allergic inflammation (56) . In addition, immune balance, which is controlled by IFN-gamma-producing Thl cells and IL-4-producing Th2 cells, plays a critical role in the regulation of airway inflammation (57) .
IL-4 is expressed with IL-3, IL-5 , IL-13, GM-CSF and some other cytokines, in TH2 subset CD4+ T-cells (58) . These cells provide help for humoral immunity and playa major role in the development of allergic/inflammatory responses, while THI cells which synthesize pro-inflammatory cytokines, play a critical role in inflammation. The role of IL-4 and related cytokines in the pathogenesis of atopy is suggested by their ability to promote the differentiation and function of mast cells, basophils and eosinophils (54) . IL-4 is the best known regulator of the immunoglobulin switch process in B cells leading to IgE secretion (59) . IL-4 synthesis is up-regulated in atopic subjects, and IL-4 overexpression in mutant mice results in increased IgE levels and the development of allergic inflammation diseases (50) .
Human mast cells are immunoreactive for IL-4, which is lost following IgE-dependent activation, indicative of release. In vitro studies shown that the mRNA for IL-4 is not expressed constitutively in dispersed human lung mast cells and, following stimulation with anti-IgE, it is detectable in only 6 h. However, no IL-4 protein is detectable (47) . In other words, an enhanced Th2 immune response and the elaboration of cytokines such as IL-4, IL-13, and IL-5 contribute to the induction of allergy and asthma (43) . Interferon-gamma, a Thl cytokine, acts in conjunction with Th2 (IL-4, IL-13, and IL-5) in maintaining chronic allergic inflammation (60) . The mechanisms leading to an enhanced Th2 response are still controversial. Th2-dominated immune responses may result from immune suppression ofT-regulatory cells as well as Thl cells. Understanding early-life immune mechanisms responsible for atopic diseases, specifically how cytokines of T-regulatory cells act to balance the Th 1 and Th2 immune response, continues to be a fruitful area of research. Blocking the effects of these pro-inflammatory cytokines might provide new therapeutic approaches for the control of allergic inflammation. Clinical trials with inhibitors of cytokines, such as IL-4, IL-5 and tumour necrosis factor-a, have had success in some studies but not others. This may reflect the design of the clinical trials, including treatments regimes and the patient population.
